N-acetylcysteine in Non-Acetaminophen Pediatric Acute Liver Failure
A Multi-center Study of the Safety and Efficacy of N-acetylcysteine in the Treatment of Acute Liver Failure in Pediatric Patients Not Caused by Acetaminophen.
Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
This PHASE3 trial investigates Acute Liver Failure and Hepatic Encephalopathy and is currently completed. National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) leads this study, which shows 7 recorded versions since 2000 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Change History
7 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE3
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE3
▶ Show 2 earlier versions
-
Feb 2017 — Jun 2018 [monthly]
Completed PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE3
First recorded
Jan 2000
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- University of Pittsburgh
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Ann Arbor, United States, Atlanta, United States, Baltimore, United States, Birmingham, United Kingdom, Boston, United States, Chicago, United States, Cincinnati, United States, Dallas, United States, Denver, United States, Houston, United States and 9 more location s